^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD22-targeted CAR-T immunotherapy

    Related drugs:
    7d
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T
    7d
    Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Sana Biotechnology | Recruiting --> Active, not recruiting | N=35 --> 6 | Trial primary completion date: Mar 2028 --> Dec 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    9d
    Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    16d
    Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT (clinicaltrials.gov)
    P2, N=23, Completed, The First Affiliated Hospital of Soochow University
    New P2 trial
    28d
    A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. (PubMed, Cancer)
    The CD22/CD19 CAR T-cell and auto-HSCT sandwich strategy represents a promising approach for the treatment of Ph-negative B-ALL in AYA and adult patients, offering high efficacy and a favorable safety profile. The trial registration is ClinicalTrials.gov identifier NCT05470777.
    P2 data • Journal
    |
    CD22 (CD22 Molecule)
    |
    CD22/CD19 CAR T
    1m
    Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. (PubMed, Cytotherapy)
    CAR T-cell expansion was similar, except for patients who had extramedullary disease with low bone marrow disease burden (n = 6 from each group), for whom BC-manufactured cells had greater expansion. In summary, while efficacy across both platforms was comparable, lower inflammatory markers in those who received Prodigy manufactured CAR T-cells suggest changes in the infusion product.
    Journal
    |
    CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    firicabtagene autoleucel (CRG-022)
    3ms
    UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=70, Recruiting, Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    sirolimus
    3ms
    Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Stanford University | Trial completion date: Jan 2037 --> May 2026 | Trial primary completion date: Jan 2037 --> May 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    KMT2A rearrangement
    |
    Orca-T • firicabtagene autoleucel (CRG-022)
    3ms
    Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Ohio State University Comprehensive Cancer Center
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    3ms
    Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2029 | Trial primary completion date: Dec 2019 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    4SCAR-T
    3ms
    NatHaLi-01: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Cellectis S.A. | Trial completion date: Nov 2027 --> Aug 2027 | Trial primary completion date: Nov 2027 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
    |
    CD20 positive
    |
    Campath (alemtuzumab) • etivelcabtagene erigedleucel (UCART20x22)
    3ms
    A Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor in Patients With CD22 B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Sheba Medical Center
    New P1/2 trial